摘要
BackgroundNovel biomarkers representing different pathobiological pathways and their role in patients with acute myocardial infarction (AMI) were studied. MethodsWe retrospectively analysed serum levels of soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), heart-type fatty acid-binding protein (H-FABP) and plasma fetuin A in blood of patients with AMI (STEMI, n = 61; NSTEMI, n = 57) compared to controls with excluded coronary artery disease (n = 76). Furthermore, detailed correlation analysis was performed. ResultsCompared with controls, in patients with STEMI and NSTEMI higher levels expressed as median of sST2 in pg/mL (STEMI: 13210<bold></bold>9, NSTEMI: 11989<bold></bold>1, control: 5248; P < 0<bold></bold>001), GDF-15 in pg/mL (STEMI: 818<bold></bold>8, NSTEMI 677<bold></bold>5, control 548<bold></bold>6; P < 0<bold></bold>001), suPAR in pg/mL (STEMI: 3461<bold></bold>1, NSTEMI: 3466<bold></bold>7, control: 2463<bold></bold>6; P < 0<bold></bold>001), H-FABP in ng/mL (STEMI: 5<bold></bold>8, NSTEMI: 5<bold></bold>4, control: 0<bold></bold>0; P < 0<bold></bold>001) and lower plasma fetuin A levels in g/mL (STEMI: 95, NSTEMI: 54, control: 116<bold></bold>6; P < 0<bold></bold>001) were detected. Correlation analysis found clinical and biochemical parameters such as ejection fraction, length of hospital stay, creatine kinase, NT-proBNP and hs Troponin T levels as well as inflammatory markers (CRP, leucocytes) to be significantly correlated with novel biomarkers. ConclusionPlasma levels of novel biomarkers were significantly elevated (sST2, GDF-15, H-FABP, suPAR) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease. Significant correlations with various clinical parameters and standard biochemical markers were found.
- 出版日期2017-9